<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Ito Y</submitter><funding>Japan Society for the Promotion of Science London</funding><funding>Basic Research Laboratory</funding><funding>Kyoto University Foundation</funding><funding>NCI NIH HHS</funding><pagination>1186-1209</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10164097</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>13(5)</volume><pubmed_abstract>Tumor heterogeneity is a major barrier to cancer therapy, including immunotherapy. Activated T cells can efficiently kill tumor cells following recognition of MHC class I (MHC-I)-bound peptides, but this selection pressure favors outgrowth of MHC-I-deficient tumor cells. We performed a genome-scale screen to discover alternative pathways for T cell-mediated killing of MHC-I-deficient tumor cells. Autophagy and TNF signaling emerged as top pathways, and inactivation of Rnf31 (TNF signaling) and Atg5 (autophagy) sensitized MHC-I-deficient tumor cells to apoptosis by T cell-derived cytokines. Mechanistic studies demonstrated that inhibition of autophagy amplified proapoptotic effects of cytokines in tumor cells. Antigens from apoptotic MHC-I-deficient tumor cells were efficiently cross-presen</pubmed_abstract><journal>Cancer discovery</journal><pubmed_title>Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell-Secreted Cytokines.</pubmed_title><pmcid>PMC10164097</pmcid><funding_grant_id>P01 CA163222</funding_grant_id><funding_grant_id>22K20758</funding_grant_id><funding_grant_id>P30 CA006516</funding_grant_id><funding_grant_id>R01 CA238039</funding_grant_id><funding_grant_id>P01 CA236749</funding_grant_id><funding_grant_id>R01 CA234018</funding_grant_id><funding_grant_id>R01 CA251599</funding_grant_id><pubmed_authors>Zhang W</pubmed_authors><pubmed_authors>Juan TY</pubmed_authors><pubmed_authors>Kyrysyuk O</pubmed_authors><pubmed_authors>Wucherpfennig KW</pubmed_authors><pubmed_authors>Pan D</pubmed_authors><pubmed_authors>Ito Y</pubmed_authors><pubmed_authors>Zhang X</pubmed_authors><pubmed_authors>Doench JG</pubmed_authors><pubmed_authors>Pyrdol JW</pubmed_authors><pubmed_authors>Liu XS</pubmed_authors></additional><is_claimable>false</is_claimable><name>Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell-Secreted Cytokines.</name><description>Tumor heterogeneity is a major barrier to cancer therapy, including immunotherapy. Activated T cells can efficiently kill tumor cells following recognition of MHC class I (MHC-I)-bound peptides, but this selection pressure favors outgrowth of MHC-I-deficient tumor cells. We performed a genome-scale screen to discover alternative pathways for T cell-mediated killing of MHC-I-deficient tumor cells. Autophagy and TNF signaling emerged as top pathways, and inactivation of Rnf31 (TNF signaling) and Atg5 (autophagy) sensitized MHC-I-deficient tumor cells to apoptosis by T cell-derived cytokines. Mechanistic studies demonstrated that inhibition of autophagy amplified proapoptotic effects of cytokines in tumor cells. Antigens from apoptotic MHC-I-deficient tumor cells were efficiently cross-presen</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 May</publication><modification>2025-04-04T03:01:11.209Z</modification><creation>2025-04-04T03:01:11.209Z</creation></dates><accession>S-EPMC10164097</accession><cross_references><pubmed>36811466</pubmed><doi>10.1158/2159-8290.CD-22-1125</doi><doi>10.1158/2159-8290.cd-22-1125</doi></cross_references></HashMap>